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http://www.biomedcentral.com/1471-2458/14/14RESEARCH ARTICLE Open AccessBeyond BMI: The “Metabolically healthy obese”
phenotype & its association with clinical/
subclinical cardiovascular disease and all-cause
mortality – a systematic review
Lara L Roberson1, Ehimen C Aneni1, Wasim Maziak3, Arthur Agatston1, Theodore Feldman1, Maribeth Rouseff2,
Thinh Tran2, Michael J Blaha4, Raul D Santos5, Andrei Sposito6, Mouaz H Al-Mallah7, Ron Blankstein8,
Matthew J Budoff9 and Khurram Nasir1,3,4,10*Abstract
Background: A subgroup has emerged within the obese that do not display the typical metabolic disorders
associated with obesity and are hypothesized to have lower risk of complications. The purpose of this review was
to analyze the literature which has examined the burden of cardiovascular disease (CVD) and all-cause mortality in
the metabolically healthy obese (MHO) population.
Methods: Pubmed, Cochrane Library, and Web of Science were searched from their inception until December
2012. Studies were included which clearly defined the MHO group (using either insulin sensitivity and/or
components of metabolic syndrome AND obesity) and its association with either all cause mortality, CVD mortality,
incident CVD, and/or subclinical CVD.
Results: A total of 20 studies were identified; 15 cohort and 5 cross-sectional. Eight studies used the NCEP Adult
Treatment Panel III definition of metabolic syndrome to define “metabolically healthy”, while another nine used
insulin resistance. Seven studies assessed all-cause mortality, seven assessed CVD mortality, and nine assessed incident
CVD. MHO was found to be significantly associated with all-cause mortality in two studies (30%), CVD mortality in one
study (14%), and incident CVD in three studies (33%). Of the six studies which examined subclinical disease, four (67%)
showed significantly higher mean common carotid artery intima media thickness (CCA-IMT), coronary artery calcium
(CAC), or other subclinical CVD markers in the MHO as compared to their MHNW counterparts.
Conclusions: MHO is an important, emerging phenotype with a CVD risk between healthy, normal weight and
unhealthy, obese individuals. Successful work towards a universally accepted definition of MHO would improve
(and simplify) future studies and aid inter-study comparisons. Usefulness of a definition inclusive of insulin sensitivity
and stricter criteria for metabolic syndrome components as well as the potential addition of markers of fatty liver and
inflammation should be explored. Clinicians should be hesitant to reassure patients that the metabolically benign
phenotype is safe, as increased risk cardiovascular disease and death have been shown.* Correspondence: Khurramn@baptisthealth.net
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It is well established that obesity continues to rise in
prevalence, nearly doubling between the years of 1980 and
2008 worldwide [1]. In the United States between 2009–
2010, the rate of obesity was 35.7% in adults and 17% in
children [2], which translates into about 78 million adults
and 12.5 million children. In literature review, obesity has
been shown to be predictive of all-cause, cardiovascular
disease (CVD), and cancer mortality [3,4]. Economically,
obesity is costly due to its direct association with morbid-
ity and mortality, with the medical costs of treating obesity
and its sequelae estimated to be $147 billion in 2009 [5].
From a clinical perspective, the question remains how to
best identify those who are at the lowest risk of developing
these obesity-related complications, and monitor them in
a cost effective way, while allocating the most resources to
those in the highest risk group.
A subgroup has been identified within the obese popula-
tion, who do not display the typical metabolic disorders
associated with obesity and are hypothesized to have lower
risk of obesity-related complications. Metabolically healthy
obesity (MHO), as it will be referred to in this review, has
been previously defined as a subgroup of obese individuals
who do not have insulin resistance, lipid disorders, or
hypertension [6]. Multiple studies indicate 10-25% of the
obese can be categorized as MHO [6,7]. Wildman et al.
used NHANES, a nationally representative sample of
adults living in the US, to examine the MHO phenotype
and found a prevalence of 32% among obese adults over
the age of 20 [8].
In this review, we aim to evaluate the MHO phenotype
in context of cardiovascular disease risk and all-cause
mortality. By conducting a systematic literature search
which selected studies assessing the association of the
MHO phenotype with all-cause mortality, CVD outcomes
and subclinical CVD, we sought to summarize the risks in
this group, and discuss the challenges faced by studies in
examining this unique population.
Methods
A systematic literature search was conducted using
Pubmed, Web of Science, and Cochrane Library. In
Pubmed, the following medical subject headings (MESH)
and free text terms were used: (“metabolically healthy” OR
“metabolically normal” OR “metabolically benign” OR “in-
sulin sensitive”) AND (“obese” OR “overweight”). The
same text word search was used in Web of Science and
Cochrane Library as in Pubmed. No restrictions were used
for publication status or date, but studies had to be peer-
reviewed to be selected. Libraries were searched until
December 2012. Studies were selected if they were written
in English, included human subjects over the age of 18, de-
fined a metabolically healthy obese/overweight group and
contained either a measure of subclinical cardiovasculardisease or a hard outcome such as death or cardiovascular
disease. Studies were excluded if they failed to include a
comparison group to the MHO, the abstract and full text
was unavailable, or were reviews, letters, and case-reports.
Studies were also excluded if they failed to define metabol-
ically healthy using either insulin sensitivity or components
of metabolic syndrome or failed to define obesity using
BMI, body fat percentage, or waist circumference. Two re-
viewers independently selected articles, and then jointly
agreed on the final studies to be included.
Results
Eligible studies
Our search identified a total of 340 studies from
Pubmed, 156 from Web of Science, and 20 from
Cochrane library. Six more studies were identified by
searching the reference lists of all full-text papers in-
cluded from the initial database search. Twenty articles
met the final inclusion criteria (Figure 1).
Cohort studies
A total of 14 cohort studies were identified which exam-
ined the MHO phenotype and mortality or cardiovascular
outcomes [9-22] (Tables 1 and 2). These studies reported
an average follow-up time of 11 years. In total, the 14
studies examined 359,137 participants, 9,865 fitting the
MHO phenotype, or 2.7% of the total population studied.
One study examined the MHO phenotype and progres-
sion of subclinical cardiovascular disease at three-year
follow-up [23]. The majority of studies examined risks
in Caucasian subjects or subjects of European descent
(n = 12). One study used an Iranian cohort [12] and one
study did not report ethnicity [13]. On average, participants
were over the age of 50 (n = 9), while a small segment of
studies reported younger average age (n = 4), or did not
report age [13]. One cohort study examined the MHO
phenotype and subclinical CVD [23] (Tables 3 and 4).
i. Definitions of MHO
Studies were examined in reference to their definition of
MHO (Table 1). In 13 of the studies, obesity was defined
as BMI ≥ 30 kg/m2. The remaining study defined obesity
as either BMI ≥ 30 kg/m2 or body fat > 25% in men and
30% in women [16]. Three studies included measures of
inflammation (either C-Reactive protein [CRP] or white
blood cell [WBC] count) in the definition of MHO
[11,15,17]. Two studies defined “metabolically healthy” as
absence of metabolic syndrome (MetS) based on the
NCEP ATP III definition of MetS without any modifica-
tion [18,19]. Five studies defined “metabolically healthy” as
absence of MetS with study specific modifications to the
MetS criteria [11,12,16,20,21]. One study used only insulin
sensitivity (IS) to define “metabolically healthy” [10]. Two
studies created a unique definition using a combination of
Records identified through 
database searching  
(n = 516) 
Additional records identified 
through other sources
(n = 6 )
Records after duplicates removed  
(n = 469)
Records screened  
(n = 469)
Records excluded  
(n = 358)  
Full-text articles assessed 
for eligibility  
(n = 111 )
Studies excluded (N=91)
No hard outcome 
or subclinical CVD 
marker (56)
No comparison 
group to MHO (18)
Case reports, not 
written in English, 
review articles, 
letters (17)
Studies included 
(n = 20)
Figure 1 Search flow chart.
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ies examined both the IS and MetS definitions of “meta-
bolically healthy” within the same study [9,13-15].
ii. Outcomes measured
a. All-cause mortality. Seven studies reported all-cause
mortality [9-11,13,16,19,23]. MHO was found to be
significantly associated with all-cause mortality in
two studies (30% of studies). Five studies used meta-
bolically healthy, normal weight (MHNW) as the
comparison group [9,13,16,19,23] of which the two
significant studies were included. Two used metabol-
ically normal, “not obese, BMI <30 kg/m2” [10,11] as
the comparison and both reported null results.
Finally, four studies controlled for physical fitness
(either reported exercise or measured cardio-
respiratory fitness) of which all reported null
results [11,16,19,24].
b. CVD mortality. Seven studies separately analyzed
CVD mortality [9-11,16,19,20,23]. Five studies
showed no statistically significant association
between MHO and CVD mortality, but pointed
towards higher CVD mortality in the MHO
[9,11,16,19,20]. Only one study (14% of reviewedstudies) found the metabolically healthy obese to
have significantly higher risk of CVD mortality [23].
The studies using “metabolically normal, not obese”
rather than “normal weight” as their comparison
group found no association between MHO and
CVD mortality [10,11].
c. Incident CVD. Nine studies examined incident CVD
events [9,12,14-19,21,23]. Incident CVD was defined
as stroke, coronary heart disease (CHD), and/or
heart failure. Three studies (33%) reported
significant increase in risk of CVD events among the
MHO [9,15,23]. Five studies showed no statistically
significant association between incident CVD and
MHO, but consistently pointed towards an
incidence of CVD in the MHO approximately 1.5
times that of the comparison group [11,12,14,17,21].
The single study which was non-significant and did
not point towards an increase in risk had a follow up
of 6 years, small sample size of 550, and measured
only incident heart failure [18].
d. Subclinical measures of CVD. Bobbioni-Harsch et al.
examined the three year progression of common
carotid intima medial thickness (CCA-IMT), a
measure of arterial wall thickness and indicator of
atherosclerotic disease progression, in a cohort of
Table 1 MHO definition; cohort studies
Study Definition of metabolically healthy obese (MHO) Definition of metabolically healthy, normal weight
(MHNW)
Katzmarzyk [19] • <3 MetS • ≤ 2 MetS criteria, normal weight (BMI 18.5-24.9 kg/m2)
• BMI ≥30 kg/m2
• Diabetics included
St-Pierre [17] • ≤2 insulin resistance syndromeA (IRS) criteria • ≤2 IRSA criteria, normal weight (BMI <25 kg/m2)
• BMI≥ 30 kg/m2
• Diabetics excluded
Meigs [14] • < 3 MetS criteria and/or IS by HOMA-IR < 75th percentile • <3 MetS criteria, normal weight (BMI < 25 kg/m2)
and/or IS, normal weight (BMI < 25 kg/m2)
• BMI≥ 30 kg/m2
• Diabetics excluded
Daly [20] • <3 MetSB • <3 MetSB , normal weight (BMI <25 kg/m2)
• BMI > 30 kg/m2
• Diabetics included
Song [21] • < 3 MetSC criteria • <3 MetSC , normal weight (BMI <25 kg/m2)
• BMI ≥30 kg/m2
• Diabetics included
Kuk [13] • ≤1 MetS criteria and/or IS by HOMA < 2.5 • ≤1 MetS criteria, normal weight (BMI < 25 kg/m2)
and/or IS, normal weight (BMI < 25 kg/m2)
• BMI≥ 30 kg/m2
• Diabetics included
Arnlov [9] • <3 MetSD criteria and/or IS by HOMA-IR <75th percentile • <3 MetSD criteria, normal weight (BMI < 25 kg/m2)
and/or IS, normal weight (BMI < 25 kg/m2)
• BMI > 30 kg/m2
• Diabetics excluded
Calori [10] •IS by HOMA-IR < 2.5 • IS, not obese (BMI < 30 kg/m2)
• BMI≥ 30 kg/m2
• Diabetics included
Voulgari [18] • < 3 MetS criteria • <3 MetS criteria, normal weight (BMI <24.9 kg/m2)
• BMI≥ 30 kg/m2
• Diabetics excluded
Hosseinpanah [12] • <3 MetSE criteria • <3 MetSE criteria, normal weight (BMI 18.5-24.9 kg/m2)
• BMI ≥30 kg/m2
• Diabetics included
Bobbioni-Harsch [23] • 0 MetS criteria • 0 MetS criteria, normal weight (BMI < 25 kg/m2)
• BMI ≥25 kg/m2
Ogorodnikova [15] •≤ 2 MetSC criteria; ≤1 of any MetSC criteria, IR by HOMA-IR >
75th percentile of all participants, or systemic inflammation
by WBC >75th percentile for all participants; or IS by
HOMA-IR ≤25th percentile among non-diabetic obese,
sex-specific
•≤ 2 MetSC criteria, normal weight (BMI 18.5-24.9 kg/m2)
or≤ 1 MetSC criteria, IR by HOMA-IR > 75th percentile of
all participants, or systemic inflammation by WBC >75th
percentile for all participants, normal weight
(BMI 18.5-24.9 kg/m2) or IS, normal weight
(BMI 18.5-24.9 kg/m2)
• BMI≥ 30 kg/m2
• Diabetics included
Hamer [11] • <2 MetSF criteria (including CRP ≥3.0 mg/L) • <2 MetSF criteria, not obese (BMI 18–29.9 kg/m2) or <2 MetSF
criteria, normal waist (≤102 cm in men, ≤88 cm in women)
• BMI ≥30 kg/m2 or waist circumference >102
cm men, >88 cm women
• Diabetics included
Roberson et al. BMC Public Health 2014, 14:14 Page 4 of 12
http://www.biomedcentral.com/1471-2458/14/14
Table 1 MHO definition; cohort studies (Continued)
Bo [22] • < IS by HOMA < 2.5 AND <3 MetSG criteria • IS, normal weight (BMI <25 kg/m2)
• BMI > 30 kg/m2
• Diabetics included
Ortega [16] • ≤1 MetSC criteria • ≤1 MetSC criteria, normal weight (BMI 18.5-24.9 kg/m2)
or • ≤1 MetSC criteria, normal body fat
(<25% men/<30% women)• Body Fat%≥ 25/30 (M/F) ORBMI≥ 30 kg/m
2
• Diabetics included
ATG ≥150 mg/dL, HDL <50 mg/dL, ≥54.5% of LDL particles with diameter <255A, Apo lipoprotein B level ≥1.36 g/L, fasting insulin level ≥ 85.2 pmol/L, blood pressure ≥
135/85 mmHg, CRP ≥3.0 mg/L; BTG and waist circumference excluded, added BMI > 30 kg/m2 into criteria;CWaist circumference excluded; DWaist circumference
excluded, added BMI ≥ 29.4 kg/m2 cut-point into criteria; EWaist circumference ≥89 cm for men and ≥91 cm for women, blood pressure ≥ 140/85 mmHg; FTG excluded,
added CRP ≥ 3 mg/L into criteria; GWaist circumference ≥94 cm for men and ≥80 cm for women, fasting plasma glucose ≥ 100 mg/dl or use of hypoglycemic therapy.
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[23] (Tables 1 and 2). At baseline and three years,
cardio-metabolic risk factors were measured. Partici-
pants were grouped by weight class and according to
their metabolic status at follow up. They were con-
sidered at-risk if they had developed one or more
cardio-metabolic risk factors. At baseline, there was
no significant difference in mean CCA-IMT between
weight classes. Among the metabolically normal at
follow-up, mean CCA-IMT was significantly higher
in obese women as compared to normal body weight
women. In regression, BMI was significantly associ-
ated with the occurrence of ≥1 cardio-metabolic risk
factors in all subgroups at follow-up. The incidence
of one or more cardio-metabolic risk factors was
57.2% in overweight and obese participants who
were metabolically normal at baseline, compared
with 31.7% of normal weight participants. Also, they
found independent of metabolic abnormalities, the
CCA-IMT was thicker in the obese and overweight,
than in the normal weight.
iii.Other considerations
a. Inflammation. A total of 5 of the 14 included studies
reported any measure of inflammation. Four studies
documented C-reactive protein (CRP) levels
[11,17,21,22]. One study used white blood cell count >
75th percentile as a marker of inflammation [15].
Hamer, Ogorodokniva and St Pierre included vascular
inflammation in the definition of metabolic health
[11,15,17]. Only one study adjusted for the presence of
vascular inflammation in predicting CVD [21]. None of
these studies reported the association of vascular in-
flammation with CVD outcomes.
b. Risk-reducing behaviors. Eight of 14 studies included
measures of exercise or fitness
[11-13,16,18,19,21,23]. One study measured cardio-
respiratory fitness by treadmill test and found that
increased physical activity offset the increased CVD
mortality seen in the MHO [19]. Seven studies uti-
lized self-reported measures of physical activity andfound that the MHO had higher physical activity
levels as compared to the MUHO. However, these
studies did not assess the effect of physical activity
alone on CVD outcomes in the metabolically healthy
obese. Only three studies documented dietary behav-
iors in the study populations [13,21,23]. All three
utilized self reported methods. Out of these, one
study found that in subjects with BMI < 30, insulin
sensitive individuals had significantly higher mean
daily fiber consumption as compared to insulin re-
sistant subjects. No significant difference was found
in fiber consumption between insulin sensitive or
resistant subjects with BMI > 30 [23].
Cross sectional studies
A total of five cross sectional studies met inclusion cri-
teria, [25-29] (Tables 3 and 4). In total 5,234 participants
were examined for prevalence of subclinical CVD in re-
lation to the MHO phenotype.
i. Definitions of MHO
All studies included diabetics. Two studies defined
obese/overweight as BMI ≥ 25 kg/m2 [27,28]. The
remaining studies used BMI > or ≥ 30 kg/m2. Two stud-
ies defined MHO using IS [25,26]. Of the remaining
three studies, one used the standard NCEP ATP III def-
inition of MetS [29], and the other two used a modified
version of the MetS definition [27,28]. One study in-
cluded CRP < 3 mg/L in the definition of “metabolically
healthy” [27].
ii Outcomes measured
a. Common carotid artery-intima medial thickness. All
five of the studies measured CCA-IMT as a marker
of atherosclerosis. Of the four studies reporting
mean difference in CCA-IMT between MHO and
MHNW individuals [25-28], two reported signifi-
cantly higher levels in the MHO [25,27]. However,
in the two studies that did not attain statistical
significance, the mean CCA-IMT tended to be
higher in the MHO group as compared to the
Table 2 Results; cohort studies
Study Subjects
(age , male)
Median follow-up
time (yrs)
Outcome Results
Katzmarzyk [19] N = 19,173 10 All-cause mortality
CVD mortality
MHO = All cause: 25 (3%); CVD: 12 (1%);
MHNW = All-cause: 160 (2%); CVD: 38 (1%);
MHO = 1,019 (43, 100%) •Unadjusted HR for MHO vs.
MHNW= NR (All-cause); NR (CVD)
MHNW= 7,153 (41, 100%) •AdjustedA HR for MHO vs.
MHNW= 0.88 (0.57-1.36) [All-cause];
1.59 (0.81-3.12) [CVD]
St-Pierre [17] N = 1,824 13 Incident CVD Total = 284 (16%); MHO = NR; MHNW = NR
MHO = 54 (NR, 100%) •Unadjusted HR for MHO vs. MHNW= NR
MHNW= 512 (NR, 100%) •AdjustedB HR for MHO vs. MHNW= 1.53 (0.79-3.00)
Meigs [14] N = 2,902 11 Incident CVD MHO = CVD: 19 (8%); MHNW = CVD: 19 (5%);
MHO = 236 (52, 51%) •Unadjusted RR for MHO vs. MHNW= NR
MHNW= 981 (52, 27%) • AdjustedC RR for MHO (MetS)
vs. MHNW= 1.48 (0.87-2.55)[CVD]
•AdjustedC RR for MHO (IS) vs.
MHNW= 1.42 (0.87-2.33) [CVD]
Daly [20] N = 8,397 (60, 87%) 4 CVD mortality MHO = NR (3%); MHNW = NR (2%)
MHO = 839 (NR,NR) •Unadjusted RR for MHO vs. MHNW= 1.42 (0.76-2.63)
MHNW= NR •Adjusted RR for MHO vs. MHNW= NR
Song [21] N = 25,626 10 Incident CVD MHO = CVD: 77 (3%); MHNW = CVD: 278 (2%)
MHO = 2,925 (54, 0%) •Unadjusted RR for MHO vs. MHNW= NR
MHNW= 12,943 (54, 0%) •AdjustedD RR for MHO vs. MHNW= 1.05 (0.66-1.66)
•AdjustedE RR for MHO vs. MHNW= 1.07 (0.68-1.70)
Kuk [13] N = 6,011 9 All-cause mortality Total = 292 (5%); MHO = NR; MHNW = NR
MHO = 78 (NR, NR) •Unadjusted RR for MHO (MetS) vs. MHNW= NR
MHNW= 1,461 (NR, NR) •AdjustedF RR for MHO (MetS) vs. MHNW= 2.80 (1.18-6.65)
•Unadjusted RR for MHO (IS) vs. MHNW= NR
•AdjustedF RR for MHO (IS) vs. MHNW= 2.58 (1.00-6.65)
Arnlov [9] N = 1,758 30 All-cause mortality MHO = All-cause: 18 (60%); CVD mortality: 5 (17%)
MHNW = All-cause: 391 (44%); CVD mortality: 155 (17%)
MHO = 30 (50, 100%) CVD mortality •Unadjusted RR for MHO (MetS) vs. MHNW= NR
MHNW= 891 (50, 100%) Incident CVD • AdjustedG RR for MHO (MetS) vs. MHNW= 1.65
(1.03-2.66) [All-cause]; 1.20 (0.49-2.93) [CVD mortality];
1.95 (1.14-3.34) [Incident CVD]
• AdjustedG RR for MHO (IS) vs. MHNW= 2.04 (1.25-3.32)
[All-cause]; 1.80 (0.79-4.08) [CVD mortality]; 1.91 (1.07-3.41)
[Incident CVD]
Calori [10] N = 2,011 15 All-cause mortality MHO = All-cause: 7 (16%); CVD: 2 (5%) MHNW = All-cause:
141 (20%); CVD: 58 (8%)
MHO = 43 (55, 28%) CVD mortality •Unadjusted HR for MHO vs. MHNW= NR
MHNW= 708 (55, 45%) •AdjustedH HR for MHO vs. MHNW= 0.99
(0.46-2.11) [All-cause]; 0.73 (0.18-3.00) [CVD]
Voulgari [18] N = 550 (60, NR) Incident heart
failure
MHO = 43 (9%); MHNW = 17 (16%)
MHO = 96 (NR, NR) 6 •Unadjusted HR for MHO vs. MHNW= 0.26 (NR)
MHNW= 109 (NR, NR) •AdjustedI HR for MHO vs. MHNW= 0.41 (0.10-1.31)
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Table 2 Results; cohort studies (Continued)
Hosseinpanah [12] N = 6,215 8 Incident CVD MHO = 13 (3%); MHNW = 64 (4%)
MHO = 408 (45, 20%) •Unadjusted HR for MHO vs. MHNW= NR
MHNW= 1,555 (45, 57%) •AdjustedJ HR for MHO vs. MHNW= 1.07 (0.59-1.96)
Bobbioni
Harsch [23]
N = 436 3 CCA-IMT Male Subjects Mean CCA-IMT at Baseline:
MHO = 0.63 (0.07) vs. MHNW= 0.59 (0.08) p = NS
MHO = 65 (45, 42%) Mean CCA-IMT at 3 years: MHO = 0.62 (0.10)
vs. MHNW= 0.60 (0.07) p = NS
MHNW= 194 (43, 23%) Female Subjects Mean CCA-IMT at Baseline:
MHO = 0.57 (0.06) vs. MHNW= 0.56 (0.06) p = NS
Mean CCA-IMT at 3 years: MHO = 0.61 (0.08) vs.
MHNW= 0.58 (0.06) p < 0.05
Ogorodnikova [15] N = 17,544 12 Incident CVD Total = 2,439 (14%); MHO = NR; MHNW = NR
MHO = 1,167 (56, 32%) •Unadjusted HR for MHO vs. MHNW= NR
MHNW= 4,036 (58, 33%) •AdjustedK HR for MHO (using various definitions)
vs. MHNW= 1.30 (1.03-1.66) [ATP III definition];
1.17 (0.87-1.57) [ATP-III Expanded];
1.52 (1.19-1.95) [IS definition]
Hamer [11] N = 22,203 7 All-cause mortality MHO = All-cause: 38 (3%); CVD: 18 (2%);
MHO = 1,160 (51.3, 53%) CVD mortality MHNW = All-cause: 777 (6%); CVD: 225 (2%)
MHNW= 12,716 (51.9, 45%) •Unadjusted HR for MHO vs. MHNW= NR
•AdjustedL HR for MHO v. MHNW= 0.91
(0.64-1.29) [All-cause]; 1.26 (0.74-2.13) [CVD]
Bo [22] N = 1,658 9 All-cause mortality MHO = All-cause: 15 (21%); CVD mortality:
8 (11%); Incident CVD: NR (8%)
MHO = 72 (55, 33%) CVD mortality MHNW = All-cause: 28 (5%); CVD mortality:7 (1%);
Incident CVD: NR (3%)
MHNW= 540 (54, 38%) Incident CVD •Unadjusted HR for MHO vs. MHNW= NR
•AdjustedM HR for MHO vs. MHNW= 1.36
(0.64-2.08) [All-cause]; 2.48(1.35-3.61) [CVD mortality];
2.76 (1.05-7.28) [Incident CVD]
Ortega [16] N = 43,265 14 All-cause mortality MHO = All-cause: 52 (3%); CVD mortality:
17 (1%); Incident CVD: 30 (6%)
MHO = 1,738 (NR, 80%) CVD mortality MHNW = All-cause: 449 (3%); CVD mortality:
98 (1%); Incident CVD: 261 (4%)
MHNW= 16,002 (NR,NR) Incident CVD •Unadjusted HR for MHO(referent) vs. MHNW= NR
•AdjustedN HR for MHO(referent) vs. MHNW= 0.91
(0.67-1.24) [All-cause]; 0.73 (0.42-1.28) [ CVD mortality];
0.78 (0.52-1.18) [Incident CVD]
AAdjusted for age, year of exam, smoking, alcohol use, possible existence of CVD, parental history or premature CVD, cardio-respiratory fitness; BAdjusted for age,
smoking, and medication use at baseline; CAdjusted for age, sex, LDL, smoking; DAdjusted for age, treatment assignment, smoking, exercise, alcohol use, total
calorie intake, postmenopausal hormone use, multivitamin use, parental history of myocardial infarction before 60 years, BMI; EAdjusted for age, treatment assignment,
smoking, exercise, alcohol use, total calorie intake, postmenopausal hormone use, multivitamin use, parental history of myocardial infarction before 60 years, CRP;
FAdjusted for age, sex, income, smoking, ethnicity, alcohol use; GAdjusted for age, smoking, and LDL; HAdjusted for age, sex; IAdjusted for age, sex, impaired glucose
tolerance, dyslipidemia, hypertension, smoking, physical inactivity, left ventricular hypertrophy, and function on echocardiography; JAdjusted for age, gender, exercise,
smoking, family history of premature CAD, high total cholesterol; KAdjusted for age, gender, race, smoking, education, alcohol use, and study cohort; LAdjusted for age,
sex, smoking physical activity, socioeconomic group, and BMI; MAdjusted for age, sex, fiber intake, exercise, waist circumference; NAdjusted for age, sex, examination year,
smoking, alcohol, parental history of CVD, fitness.
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that carotid atherosclerosis was similar among nor-
mal weight, overweight, and obese participants when
stratified by presence or absence of MetS,
b. Other subclinical measures of CVD. One study
assessed coronary artery calcium (CAC), which is an
early indicator of atherosclerotic disease measuringthe degree of calcification in the coronary arteries
[27]. Khan et al. reported higher mean levels of CAC
and increased frequency of higher CAC in the
metabolically healthy obese as compared to controls.
One study assessed liver fat, and found that the
frequency of MHO participants with fatty liver was
significantly higher than that of normal weight, but
Table 3 MHO Definition; Cross Sectional Studies
Study Definition of metabolically healthy obese (MHO) Definition of metabolically healthy, normal weight (MHNW)
Marini [25] • IS by OGTT & euglycemic clamp ≥75th percentile of all obese participants • Not obese (BMI < 27 kg/mg2)
• BMI >30
• Diabetics included
Stefan [26] • IS by OGTT ≥75th percentile of all obese participants • IS, normal weight (BMI < 25 kg/m2)
• BMI≥ 30
• Diabetics included
Irace [29] • <3 MetS criteria • <3 MetS, normal weight (BMI 18.5-25 kg/m2)
• BMI > 29.9
• Diabetics included
Khan [27] • <3 MetSA Criteria (including CRP ≥3.0 mg/L) • <3 MetSA criteria, normal weight (BMI < 25 kg/m2)
• BMI≥ 25
• Diabetics included
Park [28] • 0 MetSB criteria • 0 MetSB criteria, normal weight (BMI <23 kg/m2)
• BMI≥ 25
• Diabetics included
AWaist circumference excluded, added CRP ≥3.0 mg/L; BWaist circumference ≥90 cm for men and ≥80 cm for women, fasting glucose at least 100 mg/dL.
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participants [26]. Finally, one study also examined
multiple measures of cardiovascular changes
including left ventricular mass index(LVMI), mitral
E/A ratio, E/Ea ratio, TDI and Ea velocity [28]. Park
et al. found the MHO had significantly increased
LVMI and decreased mitral E/A ratio as compared
to the metabolically normal, normal weight
participants; indicating changes in heart structure
and function in this group [28].
iii.Other considerations
a. Inflammation. CRP was measured in two studies
[27,28] neither of which reported the association of
CRP and CVD outcomes in the context of metabolic
health and obesity. Khan et al. included vascular
inflammation (VI) in the definition of metabolic
syndrome [27]. Park adjusted for VI in predicting
subclinical CVD outcomes studied [28].
Discussion
The purpose of the present study was to review the lit-
erature that has examined the relationship between the
metabolically healthy obese phenotype and cardiovascu-
lar disease. The most common definition of MHO used
was having a BMI ≥ 30 kg/m2 and less than 3 MetS cri-
teria (8 studies). Nine studies also included insulin sensi-
tivity in the definition of MHO. The most commonly
used comparison group was MHNW defined as having a
BMI < 25 kg/m2 and meeting < 3 MetS criteria (9 stud-
ies). Of the fourteen studies identified examining CVDoutcomes or all-cause mortality, most were not able to
demonstrate a significant association between MHO and
increased risk of CVD and mortality. However, a trend
towards a slight increase in risk in all but one study was
observed, which was supported by increased subclinical
disease burden observed in the cross-sectional studies.
In the six studies measuring subclinical CVD, the MHO
phenotype was associated with increased subclinical
CVD burden in four, and this association achieved statis-
tical significance. It appears that MHO individuals have
a slightly increased CVD risk as compared to their nor-
mal weight counterparts, but the results are mixed as
can be seen from the studies reviewed here. It is difficult
to determine whether the mixed findings are a result of
methodological issues (such as variable follow-up dur-
ation, small sample size, non-standardized comparison
groups, outcome measurement, etc.) or due to a truly
weak effect. Therefore, there is a pressing need for estab-
lishing a streamlined, central definition of “metabolically
healthy obese” in future studies.
Defining “metabolically healthy obese”
As mentioned previously, the definitions of MHO are
quite heterogeneous and make quantitative synthesis of
the reviewed studies difficult. One of the first to identify
and review this phenotype in 2001, was Sims [30], who
highlighted visceral adiposity and insulin resistance as key
determinants of MHO. In the literature analyzed for this
review, the most commonly applied definition was the ab-
sence or presence of MetS in conjunction with obesity
(measured via BMI). IR was often ignored and replaced
with fasting glucose. BMI, though a useful tool for
Table 4 Results; Cross Sectional Studies
Study Subjects (Age, Male) Outcome Results
Marini [25] N = 153 CCA-IMT Mean CCA-IMT: MHO = 0.79 (0.08) vs. MHNW= 0.61 (0.11) p < 0.001
MHO = NR (35, 0%)
MHNW= 73 (34, 0%)
Stefan [26] N = 314 CCA-IMT Mean CCA-IMT: MHO = 0.54 (0.02) vs. MHNW= 0.51 (0.02) p = NS
MHO = 31 (47, 39%)
MHNW= 54 (45, 17%)
Irace [29] N = 1842 (30–80 years old, 55%) MHO = NR CCA-IMT Mean CCA-IMT: MHO = NR vs. MHNW= NR
MHNW=NR • AdjustedA OR of CCA-IMT MetS: 1.42 (1.10-1.83) p = 0.01BMI: p = NS
Khan [27] N = 475 CCA-IMT Mean CCA- IMT: MHO = 0.68 (0.09) vs. MHNW =0.64 (0.08) p < 0.001
MHO = 260 (51, 0%) aPWV Mean aPWV: MHO = 809.9 (182.3) vs. MHNW =731 (176.4) p < 0.001
MHNW= 145 (51, 0%) CAC Frequency (%) with increased CAC: MHO = 53 (20%) vs.
MHNW =13 (9%) p < 0.001
AC Frequency (%) with increased AC: MHO = 130 (50%) vs.
MHNW =47 (32%) p < 0.001
•AdjustedB OR's of CAC and AC associated with MHO vs.
MHNW CAC: 2.38 (1.20,4.70) p = 0.01; AC: 2.37 (1.49.3.80) p < 0.001
•AdjustedB regression coefficients associated with MHO vs.
MHNW CCA-IMT: 0.034 p < 0.001; aPWV: 59.7 p = 0.001
Park [28] N = 2540 MHO = 71 (52, 45%) CCA-IMT Mean CCA IMT: MHO = 0.72 (0.06) vs. MHNW= 0.70 (0.06) p = NS
MHNW= 286 (52, 52%) aPWV Mean aPWV: MHO = 12.8 (1.1) vs. MHNW= 12.9 (1.6) p = NS
LVMI Mean LVMI: MHO = 42.4 (7.4) vs. MHNW= 35.4 (6.6) p < 0.01
E/A ratio Mean E/A ratio: MHO = 1.17 (0.34) vs. MHNW= 1.34 (0.41) p < 0.05
AAdjusted for age, sex, smoking, metabolic syndrome, BMI, LDL; BAdjusted for age, site of recruitment, education, race, smoking; CAdjusted for age, sex, heart rate,
CRP, medication for hypertension, treatment for diabetes mellitus.
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discriminate between lean muscle and fat, or fat distribu-
tion. Waist circumference, however, provides an estimate
of visceral adiposity which many studies have shown to be
significantly associated with IR, type 2 diabetes, and car-
diovascular events [31]. Fasting glucose, used in the diag-
nosis of MetS, has limitations in that in only provides a
snap-shot of glucose regulation [32]. Ideally, IR should be
measured using the gold standard diagnostic test, the
hyperinsulinemic euglycemic glucose clamp (HEGC) [33].
However, this procedure is costly, labor intensive for the
investigator, and largely uncomfortable for the patient. Less
invasive, but still labor intensive tests such as HOMA-IR or
the quantitative insulin sensitivity check index (QUICKI)
have been shown to produce similar results and may be
useful substitutes for HEGC.
Two often-discussed points in MHO are inflammation
as measured by C-reactive protein (CRP) and fatty liver
or non-alcoholic fatty liver disease (NAFLD). Inflamma-
tion has been shown to promote IR [34]. CRP is thought
to be the best biomarker of vascular inflammation and
has been shown to be predictive of CVD events [34,35].
In the studies reviewed here, 4 studies included CRP in
the definition of MHO, but none of them assessed the
relationship of VI and CVD risk. Therefore, the usefulnessof CRP as part of the definition of MHO, or as a predictor
of CVD events in the metabolically healthy obese remains
uncertain in the studies reviewed here. It is difficult to
draw conclusions regarding the usefulness of including VI
in the definition of metabolic health or its role as a pre-
dictor of CVD from the studies included in this review.
Absence of NAFLD has also been explored as a potential
identifier of MHO. Fatty liver has been implicated as con-
tributing to IR, and has been associated with increased
risk of incident cardiovascular disease even when control-
ling for metabolic syndrome and obesity [36,37]. Messier
et al. found that the MHO had lower liver fat content than
their “at-risk” obese equivalents [38]. One study reviewed
examined fatty liver in the MHO and found them to have
a prevalence of NAFLD similar to overweight participants
and greater than those in the normal weight category [26].
Going forward, liver fat could prove a useful tool to diag-
nose and assess metabolic health of the obese, especially
when other metabolic abnormalities are absent. NAFLD
can be assessed non-invasively using ultrasound, and pro-
vides an early diagnostic marker for cardiovascular disease
risk. More long-term studies are needed to confirm its
usefulness in the MHO population.
Future studies would be well served to use an increas-
ingly strict definition of MHO which requires measures of
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while still including information on blood pressure, fasting
glucose, cholesterol, triglycerides, liver fat, and inflamma-
tion. To show a greater difference in risk, defining MHO
as having none of the components may have greater util-
ity. St-Pierre et al. found the relative risk of ischemic heart
disease increased linearly with increasing number of meta-
bolic abnormalities [17]. No study reviewed used 0 MetS
components to define MHO. However, among the three
cohort studies which used ≤1 MetS criteria in the defin-
ition of MHO, only one showed statistically significant dif-
ference in the MHO as compared to MHNW [13].
Equally important as defining MHO is the need to de-
termine appropriate comparison groups. In this review,
we chose to look at only the comparison between MHO
and the “healthiest” group. This was defined as the
metabolically healthy, normal weight participants (BMI
< 25 kg/m2) in most studies; however, some studies
chose to use only normal weight individuals with no re-
port of metabolic health, or included overweight individ-
uals in the comparison group. Using these parameters,
“unhealthy” traits may have leaked into the “healthiest”
groups, leading to crossover bias in analysis which would
make true differences between these groups more diffi-
cult to detect. No study has compared CVD risks in the
MHO by class of obesity. Soverini et al. examined the
prevalence of metabolic syndrome and insulin resistance
in morbidly obese patients, and found a small percent-
age maintained insulin sensitivity even at BMI > 40 kg/
m2 [39]. When comparing MHO to the healthiest, the
sickest, or even an intermediary (metabolically unhealthy
and normal weight), this review stresses the importance
of a well defined comparison group in order to make in-
ferences relevant to the general population.
Subclinical disease measures
When assessing intermediate risk populations such as the
obese, the usefulness of traditional risk factor assessment
(such as Framingham) diminishes. Measures of subclinical
disease are increasingly important as they provide a view
of actual disease progression and more accurate event pre-
diction than traditional CVD risk factors. The most com-
mon subclinical disease measures used are CCA-IMT,
CAC, ankle-brachial index (ABI), and endothelial func-
tion. CCA-IMT was the most commonly studied measure
of subclinical disease in the studies reviewed. A majority
of the studies documented a significant trend towards in-
creased IMT in MHO versus controls. The rising gold
standard for measuring degree of atherosclerosis is CAC.
Only one study in our analysis measured CAC and found
it was significantly increased in the MHO. No study to
date has examined whether the differences in outcome
(incident CVD and CVD mortality) can be explained
by differences in subclinical CVD. In the studies whichexamined subclinical disease, all except one were cross-
sectional in design, which gives us a snapshot of subclin-
ical disease in the MHO, but does not allow us to examine
the progression of disease. The prospective study by
Bobbioni-Harsh et al. gave important insights into the de-
velopment and progression of subclinical disease among
the metabolically healthy obese, showing faster progres-
sion of subclinical CVD, independent of metabolic abnor-
malities [23]. Cohort studies allow us to see the time
sensitive component of obesity, and the progressive devel-
opment of cardiovascular risk factors. Future follow-up
studies are needed which include multiple measures of
subclinical CVD at baseline and follow-up and examine
MHO in context of increased burden as compared to their
normal weight counterparts.
Expanding the subject population
Cardiovascular disease prevalence, morbidity, and mortal-
ity difference are well established across racial/ethnic and
socioeconomic lines [40,41]. Surveillance data from
NHANES and BRFSS indicate African Americans experi-
ence higher death rates due to both heart disease and
stroke [40]. Likewise, Hispanics and Non-Hispanic blacks
have higher levels of obesity as compared to Non-Hispanic
whites [2]. Of the current studies reviewed, all but one
assessed CVD risk in the MHO phenotype in participants
of mainly Caucasian or European descent. Surveillance
data likewise indicates the prevalence of heart disease,
hypertension, and stroke in those persons with incomes
below the poverty threshold, is significantly greater than
those at or above the poverty threshold [41]. We did not
identify any study which examined the prevalence of the
MHO phenotype in association with CVD risk in the
MHO across racial or socioeconomic lines. Thus, there is
an urgent need for longitudinal studies with socioeconomi-
cally diverse, multi-ethnic populations in order to correctly
identify the CVD risk of the MHO group.
Mechanisms of MHO
Behavioral and lifestyle factors may play a large role in
why a subset of the obese do not present with metabolic
abnormalities or present them at a slower pace. However,
this is a topic which has not been studied at length and
presents mixed findings. Seven of the eight studies meas-
uring physical activity found increased activity in the
metabolically healthy obese, when compared to the meta-
bolically unhealthy obese. In addition, several studies
found that increased physical activity offset the increased
risk of CVD in the MHO. This suggests that all studies
examining the MHO phenotype should also assess phys-
ical activity, as physical activity appears to nullify the effect
of MHO on CVD risk. Hankinson et al. found no differ-
ence between diet factors, and physical activity reported
between MHO and unhealthy obese participants [42].
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ical activity increased the odds of presenting with the
MHO phenotype among obese participants [38]. A review
by Gill found that increasing physical activity reduced IR,
a key factor in defining MHO [43]. While most studies
measured physical activity by self report, more accurate
results are obtained when physical fitness is directly mea-
sured. Ortega et al. measured cardio-respiratory fitness by
treadmill test and found MHO participants had signifi-
cantly higher VO2 max when compared to the metabolic-
ally unhealthy obese [16]. Recent research on sedentary
behavior, independent of physical activity, has shown that
increased sedentary time is associated with increased risk
of diabetes, cardiovascular events, and cardiovascular as
well as all-cause mortality [44]. This is in agreement with
the belief that the natural tendency of the MHO is to pro-
gress to MUHO when physical activity is stopped or re-
duced [45]. To date, no study has examined sedentary
time in the MHO phenotype.
Future research should also target genetic studies to illu-
minate why some obese individuals do not develop or ex-
perience delayed development of metabolic syndrome. For
example, one study in mice found that extremely obese
mice with a mutation in the Brd2 gene are protected from
developing type 2 diabetes mellitus [46]. This could provide
a clue as to why certain obese individuals do not seem to
develop the metabolic abnormalities associated with obes-
ity. However, the search for relevant genes in human
models continues. It is likely that a gene-environment inter-
action is at play, similar to the model suggested for the de-
velopment of obesity [47]. More follow-up studies are
needed to examine the transition between MHO and meta-
bolically unhealthy and obese, and whether genetics and
lifestyle factors play a role in both development and reversal
of such. Likewise, studies conducted in aging cohorts would
give insight into the prevalence of this phenotype in the
elderly, clarifying the time-dependent relationship of obesity
and metabolic abnormality presentation.
Conclusion
MHO is an important, emerging phenotype with risks
somewhere intermediate between healthy, normal weight
and unhealthy, obese individuals. Successful work towards
a universally accepted definition of MHO would improve
(and simplify) future studies and strengthen inter-study
comparisons. Usefulness of a definition inclusive of insulin
sensitivity in concert with stricter criteria for metabolic
syndrome components should be explored, as well as the
potential inclusion of fatty liver. As obesity continues to
rise, this phenotype will become increasingly important.
Clinicians exercise caution in reassuring patients that the
metabolically benign phenotype is safe, as increased risk of
cardiovascular events and death remains a possibility
based on the limited data reviewed.Abbreviations
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